FDA Recalls Orphenadrine Citrate Tablets Due to Nitrosamine Impurity
Sandoz is recalling Orphenadrine Citrate Extended-Release Tablets due to nitrosamine impurity levels exceeding acceptable daily limits. Affected patients should consult their healthcare provider.
- Product
- ORPHENADRINE CITRATE — ORPHENADRINE CITRATE (ORPHENADRINE CITRATE)
- Category
- Drug
- Distribution
- Distributed nationwide